| Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features D Sia, Y Jiao, I Martinez-Quetglas, O Kuchuk, C Villacorta-Martin, ... Gastroenterology 153 (3), 812-826, 2017 | 681 | 2017 |
| Cardiometabolic risk loci share downstream cis-and trans-gene regulation across tissues and diseases O Franzén, R Ermel, A Cohain, NK Akers, A Di Narzo, HA Talukdar, ... Science 353 (6301), 827-830, 2016 | 248 | 2016 |
| Intratumoral heterogeneity and clonal evolution in liver cancer B Losic, AJ Craig, C Villacorta-Martin, SN Martins-Filho, N Akers, X Chen, ... Nature communications 11 (1), 291, 2020 | 229 | 2020 |
| Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21. 32 L Conde, E Halperin, NK Akers, KM Brown, KE Smedby, N Rothman, ... Nature genetics 42 (8), 661-664, 2010 | 178 | 2010 |
| Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region CF Skibola, SI Berndt, J Vijai, L Conde, Z Wang, M Yeager, ... The American Journal of Human Genetics 95 (4), 462-471, 2014 | 121 | 2014 |
| Phase 2 trial of gemcitabine, cisplatin, plus ipilimumab in patients with metastatic urothelial cancer and impact of DNA damage response gene mutations on outcomes MD Galsky, H Wang, NM Hahn, P Twardowski, SK Pal, C Albany, ... European urology 73 (5), 751-759, 2018 | 114 | 2018 |
| Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple … T Ching, ME Duncan, T Newman-Eerkes, MME McWhorter, JM Tracy, ... BMC cancer 20 (1), 1-15, 2020 | 72 | 2020 |
| Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications J Carrillo-Reixach, L Torrens, M Simon-Coma, L Royo, M Domingo-Sàbat, ... Journal of hepatology 73 (2), 328-341, 2020 | 63 | 2020 |
| Associations between arsenic (+3 oxidation state) methyltransferase (AS3MT) and N‐6 adenine‐specific DNA methyltransferase 1 (N6AMT1) polymorphisms … R De la Rosa, C Steinmaus, NK Akers, L Conde, C Ferreccio, D Kalman, ... Environmental and molecular mutagenesis 58 (6), 411-422, 2017 | 45 | 2017 |
| Multi‐locus HLA class I and II allele and haplotype associations with follicular lymphoma CF Skibola, NK Akers, L Conde, M Ladner, SK Hawbecker, F Cohen, ... Tissue antigens 79 (4), 279-286, 2012 | 39 | 2012 |
| STAR Chimeric Post for rapid detection of circular RNA and fusion transcripts NK Akers, EE Schadt, B Losic Bioinformatics 34 (14), 2364-2370, 2018 | 30 | 2018 |
| Coding variants at hexa-allelic amino acid 13 of HLA-DRB1 explain independent SNP associations with follicular lymphoma risk JN Foo, KE Smedby, NK Akers, M Berglund, ID Irwan, X Jia, Y Li, L Conde, ... The American Journal of Human Genetics 93 (1), 167-172, 2013 | 30 | 2013 |
| Common variants within 6p21. 31 locus are associated with chronic lymphocytic leukaemia and, potentially, other non‐H odgkin lymphoma subtypes SL Slager, NJ Camp, L Conde, TD Shanafelt, SJ Achenbach, KG Rabe, ... British journal of haematology 159 (5), 572-576, 2012 | 17 | 2012 |
| Association of HLA-DQB1 alleles with risk of follicular lymphoma NK Akers, JD Curry, L Conde, PM Bracci, MT Smith, CF Skibola Leukemia & lymphoma 52 (1), 53-58, 2011 | 15 | 2011 |
| Follicular lymphoma-protective HLA class II variants correlate with increased HLA-DQB1 protein expression FCM Sillé, L Conde, J Zhang, NK Akers, S Sanchez, J Maltbaek, JE Riby, ... Genes & Immunity 15 (2), 133-136, 2014 | 10 | 2014 |
| Integrative analysis of loss-of-function variants in clinical and genomic data reveals novel genes associated with cardiovascular traits BS Glicksberg, L Amadori, NK Akers, K Sukhavasi, O Franzén, L Li, ... BMC Medical Genomics 12, 1-16, 2019 | 8 | 2019 |
| Tumor fitness, immune exhaustion and clinical outcomes: impact of immune checkpoint inhibitors A Bubie, E Gonzalez-Kozlova, N Akers, A Villanueva, B Losic Scientific Reports 10 (1), 5062, 2020 | 6 | 2020 |
| DNA damage response (DDR) gene mutations (mut), mut load, and sensitivity to chemotherapy plus immune checkpoint blockade in urothelial cancer (UC). MD Galsky, AV Uzilov, RB McBride, H Wang, VG Patel, J Sfakianos, ... Journal of Clinical Oncology 35 (6_suppl), 300-300, 2017 | 6 | 2017 |
| Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma J Abril-Fornaguera, L Torrens, C Andreu-Oller, J Carrillo-Reixach, ... Molecular Cancer Therapeutics 22 (4), 485-498, 2023 | 3 | 2023 |
| Multiplexed, ligation‐dependent probe amplification for rapid and inexpensive HLA‐DQB1 allelotyping NK Akers, JD Curry, MT Smith, PM Bracci, CF Skibola Tissue antigens 78 (4), 275-280, 2011 | 3 | 2011 |
